Clinical Trial Initiated to Evaluate Trigonelline Monohydrate on NAD+ Metabolism in Healthy Adults
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
A new clinical trial has been registered to evaluate the safety, pharmacokinetics, and NAD+-boosting capacity of trigonelline monohydrate in healthy adults, marking an expansion of clinical research into alternative NAD+ precursors.
What happened
A clinical study titled 'Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults' has been registered on ClinicalTrials.gov.
The trial is designed to assess the safety, tolerability, and pharmacokinetic profile of trigonelline monohydrate, alongside its direct effects on NAD+ metabolism in a cohort of healthy adult participants.
Why it matters
NAD+ decline is a well-established hallmark of metabolic and biological aging, making NAD+ precursors major targets for longevity intervention.
While nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the most widely studied precursors, investigating alternative precursors such as trigonelline monohydrate could unveil distinct pharmacokinetic properties, tissue-specific distributions, or tolerability profiles.
Market impact
The clinical progression of alternative precursors like trigonelline monohydrate introduces potential competition for established players in the NAD+ space.
A successful trial could challenge the market dominance of nicotinamide riboside, represented by commercial developers such as ChromaDex, and influence the development pipelines of developers working on pharmaceutical-grade NAD+ therapeutics, such as Metro International Biotech.
What comes next
The disclosure of pharmacokinetics and safety data from this study, which will define how effectively trigonelline monohydrate raises systemic NAD+ levels relative to existing precursors.
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- ChromaDex
Sector exposure · COMPETITIVE · TECHNOLOGY
ChromaDex is a major commercial developer of nicotinamide riboside to support NAD+ biosynthesis. Clinical evaluations of alternative precursors such as trigonelline monohydrate represent thematic competition and potential technological diversification in the NAD+ landscape. (LONGEFI analysis)
- Metro International Biotech
Sector exposure · COMPETITIVE · TECHNOLOGY
Metro International Biotech develops pharmaceutical-grade NAD+ precursors aimed at NAD+ biosynthesis. The introduction of trials studying alternative precursors like trigonelline monohydrate could influence the clinical and commercial positioning of advanced candidates like MIB-626. (LONGEFI analysis)
Sources
- U.S. National Library of MedicineCLINICALTRIALS:LONGEVITY